Progyny (PGNY) to Release Earnings on Tuesday

Progyny (NASDAQ:PGNY) will likely be posting its quarterly earnings results after the market closes on Tuesday, February 25th. Analysts expect Progyny to post earnings of $0.36 per share and revenue of $277.31 million for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Progyny Trading Down 2.8 %

Shares of PGNY stock opened at $23.20 on Friday. The business’s 50 day moving average is $19.84 and its two-hundred day moving average is $18.61. Progyny has a twelve month low of $13.39 and a twelve month high of $40.89. The company has a market capitalization of $1.98 billion, a P/E ratio of 40.00, a price-to-earnings-growth ratio of 2.39 and a beta of 1.34.

Insider Buying and Selling

In related news, CEO Peter Anevski purchased 209,500 shares of the business’s stock in a transaction dated Monday, December 23rd. The stock was bought at an average cost of $14.48 per share, with a total value of $3,033,560.00. Following the completion of the acquisition, the chief executive officer now directly owns 441,463 shares in the company, valued at $6,392,384.24. The trade was a 90.32 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman David J. Schlanger purchased 150,000 shares of the business’s stock in a transaction dated Thursday, December 26th. The stock was bought at an average cost of $14.68 per share, with a total value of $2,202,000.00. Following the completion of the acquisition, the chairman now owns 228,269 shares of the company’s stock, valued at approximately $3,350,988.92. The trade was a 191.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

PGNY has been the topic of a number of analyst reports. Barclays decreased their price target on Progyny from $30.00 to $17.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Bank of America lifted their price target on Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Canaccord Genuity Group decreased their price target on Progyny from $18.00 to $17.00 and set a “hold” rating on the stock in a research note on Wednesday, November 13th. Truist Financial restated a “hold” rating and issued a $19.00 price target (down from $26.00) on shares of Progyny in a research note on Wednesday, November 13th. Finally, JPMorgan Chase & Co. lifted their price target on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Nine research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $25.83.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.